Inhibiting L-amino acid transporter 2 (LAT2) or treating tumor cells with LAT inhibitors can downregulate the expression of CD47, enhance macrophage infiltration and phagocytosis of tumor cells, and improve cancer treatment by interfering with LAT2-mediated amino acid uptake (117). Here, CD47 is linked to neoplasm.